

# *Results for announcement to the market*

## Healius Limited

ACN 064 530 516

*Appendix 4E – Preliminary Final Report (Unaudited)*

For the year ended 30 June 2025

---

CONTENTS	PAGE
Review of operations	3
Consolidated statement of profit or loss	11
Consolidated statement of other comprehensive income	12
Consolidated statement of financial position	13
Consolidated statement of changes in equity	14
Consolidated statement of cash flows	16
Notes to Appendix 4E	17
Compliance Statement	27

# Healius Limited

## Appendix 4E – Preliminary Final Report (Unaudited)

### Results for announcement to the market

For the year ended 30 June 2025

\$M	2025 TOTAL	2024 <sup>4</sup> TOTAL	\$ CHANGE 2025 VS 2024	% CHANGE 2025 VS 2024
Revenue from continuing operations	1,344.2	1,271.8	72.4	5.7%
Underlying loss for the year after tax <sup>1</sup>	(24.8)	(15.8)	(9.0)	57.0%
Loss for the year after tax from continuing operations	(563.0)	(670.0)	107.0	(16.0%)
Loss for the year after tax	(151.2)	(645.8)	494.6	(76.6%)
<b>CENTS PER SHARE <sup>2</sup></b>	<b>2025 TOTAL</b>	<b>2024<sup>4</sup> TOTAL</b>		
Basic loss per share	(20.8)	(97.9)		
Underlying basic loss per share	(3.4)	(2.4)		
Diluted loss per share	(20.8)	(97.9)		
Underlying diluted loss per share	(3.4)	(2.4)		
Interim dividend per share	-	-		
Special dividend per share	41.3	-		
Final dividend per share <sup>3</sup>	-	-		
	41.3	-		

<sup>1</sup> A reconciliation between reported loss and underlying loss after tax is contained in the following Review of Operations of this preliminary final report for the year ended 30 June 2025.

<sup>2</sup> Weighted average number of shares at 30 June 2025 determined to be 726.1 million for basic and diluted earnings per share calculations. Refer to Note 6 for further information on earnings per share.

<sup>3</sup> No final dividend is expected to be paid for the year ended 30 June 2025.

<sup>4</sup> The Lumus Imaging business has been presented as a discontinued operation for the year ended 30 June 2025, with comparatives restated accordingly.

## Review of operations for the year ended 30 June 2025

This Review of Operations includes an analysis and description of Underlying results which are defined as Reported results adjusted for non-underlying items. The Directors believe that presentation of Underlying results (non-IFRS (International Financial Reporting Standards) financial information) is useful for investors to understand the entity's core results from operations. A reconciliation of underlying to reported results for the year ended 30 June 2025 is set out on page 4 and Note 2 of this preliminary final report.

	2025 \$M	2024 \$M	BETTER/(WORSE) %
<b>Revenue (Underlying)</b>	<b>1,344.5</b>	<b>1,272.2</b>	<b>5.7%</b>
<b>EBITDA (Underlying)</b>	<b>239.3</b>	<b>249.4</b>	<b>(4.0%)</b>
D&A	(222.2)	(225.9)	1.6%
<b>EBIT (Underlying)</b>	<b>17.1</b>	<b>23.5</b>	<b>(27.2%)</b>
Non-underlying items	(32.0)	(42.5)	24.7%
Goodwill impairment	(495.2)	(603.2)	17.9%
Transactions with discontinued operations	(16.9)	(16.2)	(4.3%)
<b>EBIT (Reported)</b>	<b>(527.0)</b>	<b>(638.4)</b>	<b>17.4%</b>
Interest	(65.1)	(60.4)	(7.8%)
Tax benefit	29.1	28.8	1.0%
Profit from discontinued operations	411.8	24.2	1601.7%
<b>NPAT (Reported)</b>	<b>(151.2)</b>	<b>(645.8)</b>	<b>76.6%</b>

## MARKET CONDITIONS

The healthcare service industry, and particularly the diagnostic services industry, in which Healius operates, is an environment facing sustained high inflationary cost pressures, which is exacerbated by a Medicare funding model which has not been indexed for 25 years. Partial indexation commenced on 1 July 2025.

GP attendances were up 2.1% on the prior corresponding period (pcp), and Specialist attendances were up 2.7% over the same timeframe.

Industry fundamentals and underlying demand drivers remain positive and demand for healthcare services continues to grow, driven by an ageing population with increased prevalence of chronic diseases, more complex health issues and technological advances. Pathology continues to play a pivotal role in preventing and treating disease, and these drivers are expected to underpin growth in the medium to long-term.

## HEALIUS RESULTS

Group underlying revenue improved 5.7% in FY 2025, supported by volume and fee growth in Pathology. In 2H 2025, our Queensland and Northern NSW volumes were adversely impacted by Cyclone Alfred. Laboratories and Collection Centres were closed for several days due to safety concerns with an estimated EBIT impact of \$3.5 million.

FY 2025 underlying EBIT was \$17.1 million, with an EBIT margin of 1.3%. Earnings and margins in this financial year reflect a new strategic direction for the Pathology business, the benefit of which is expected to be realised in future periods as set out in the Investor Day held in March 2025.

The Group sold the Lumus Imaging business on 1 May 2025, and the results of the business have been presented as discontinued operations. Underlying EBIT excludes discontinued operations, transaction and separation costs associated with the Lumus Imaging sale, and other non-underlying items as noted below.

Interest costs of \$65.1 million were 7.8% higher than pcp, primarily due to increases in average debt levels and the cost of borrowing. Debt was repaid in full post the sale of Lumus Imaging.

Reported revenue excludes transactions with discontinued operations. The reconciliation between underlying and reported revenue is set out below:

	2025 \$M	2024 \$M
Underlying revenue	1,344.5	1,272.2
Transactions with discontinued operations	(0.3)	(0.4)
<b>Reported revenue</b>	<b>1,344.2</b>	<b>1,271.8</b>

Reported EBIT includes items which Healius has identified as non-underlying and transactions with discontinued operations. The reconciliation between underlying and reported EBIT is set out below:

	2025 \$M	2024 \$M
<b>Underlying EBIT</b>	<b>17.1</b>	<b>23.5</b>
Digital transformation costs	(19.6)	(25.8)
Transaction and takeover bid costs	(1.6)	(7.5)
Restructuring and other costs	(10.8)	(9.2)
<b>Non-underlying items</b>	<b>(32.0)</b>	<b>(42.5)</b>
Impairment of goodwill	(495.2)	(603.2)
<b>Non-cash impairment charges</b>	<b>(495.2)</b>	<b>(603.2)</b>
Transactions with discontinued operations	(16.9)	(16.2)
<b>Reported EBIT</b>	<b>(527.0)</b>	<b>(638.4)</b>

The adjustments between underlying and reported EBIT are as follows:

- Digital costs of \$19.6 million are part of the multi-year digital transformation program. The non-underlying accounting treatment will cease from 1 January 2026 as the program ends and digital costs become business as usual expenses.
- Transaction and takeover bid costs of \$1.6 million relate to deferred payments for earlier acquisitions.
- Restructuring and other costs of \$10.8 million primarily relate to the consolidation of group support functions and to right-sizing the business post the sale of Lumus Imaging.

## Review of operations for the year ended 30 June 2025

- As required by accounting standards, a non-cash impairment charge of \$495.2 million against goodwill in the Pathology division has been recognised in FY 2025.

Reported loss after tax excludes transactions with discontinued operations and non-underlying items. The reconciliation between underlying and reported loss after tax is set out below:

	2025 \$M	2024 \$M
<b>Underlying EBIT</b>	<b>17.1</b>	<b>23.5</b>
Interest	(65.1)	(60.4)
Notional interest recharged to Lumus Imaging	12.6	14.3
Tax benefit @ 30%	10.6	6.8
<b>Underlying loss after tax</b>	<b>(24.8)</b>	<b>(15.8)</b>
After-tax adjustments to underlying EBIT	(369.0)	(452.0)
Tax differential for non-deductible items	(148.6)	(180.9)
Transactions with discontinued operations, net of tax	(11.8)	(11.3)
Notional interest recharged to Lumus Imaging, net of tax	(8.8)	(10.0)
Profit from discontinued operations	411.8	24.2
<b>Reported loss after tax including discontinued operations</b>	<b>(151.2)</b>	<b>(645.8)</b>

## DIVISIONAL RESULTS

### PATHOLOGY

UNDERLYING	2025 \$M	2024 \$M	BETTER/(WORSE) %
Revenue	1,302.1	1,228.6	6.0%
EBITDA	244.2	251.7	(3.0%)
Depreciation and amortisation	(216.0)	(218.4)	1.1%
EBIT	28.2	33.3	(15.3%)

Pathology revenue was up \$73.5 million or 6.0% on pcp, which was driven by an increase in average fee across all segments and volume growth of 3.3% for the year. Pathology revenue growth of 5.1% in 2H 2025 was despite a modest volume increase of 1.6%. This growth was attributable to changing revenue mix with growth in Specialist revenues and strong growth in areas such as Genomics, Veterinary Pathology and Clinical Trials resulting in an average fee increase.

Tropical Cyclone Alfred impacted 2H 2025 EBIT by \$3.5 million, with laboratories and collection centres in Queensland and Northern New South Wales closed for several days due to safety concerns for our team members.

EBIT improved significantly in 2H 2025 to \$24.1 million, with an EBIT of \$28.2 million for FY 2025 (or \$31.7m adjusting for the estimated impact of Tropical Cyclone Alfred). The EBIT margin for FY 2025 was 2.2% and improved to 3.6% for 2H 2025 (or 4.1% adjusting for the impact of Tropical Cyclone Alfred).

Growth in GP attendances has supported revenue growth in the GP segment, which was further complemented by volume growth in our B2B and Specialists segments. Healus continues to focus on growing its Specialists segment, targeting genomics and haematology which are generating higher value referrals.

Inflationary pressures remain a constant issue, with labour costs running at almost half of pathology revenues. A detailed labour optimisation program, including collection centre opening hours and productivity measures was undertaken and completed in 2H 2025. This detailed plan is now being implemented across our network and showing benefits. Labour costs are forecast to remain broadly flat year-on-year.

As required by Accounting Standards, a non-cash impairment charge of \$495.2 million against goodwill in the Pathology division has been recognised in FY 2025.

The T27 forecast for high single digit margins by June 2027 as presented at the March 2025 Investor Day remains unchanged.

## Review of operations for the year ended 30 June 2025

### AGILEX BIOLABS

UNDERLYING	2025 \$M	2024 \$M	BETTER/(WORSE) %
Revenue	38.2	39.5	(3.3%)
EBITDA	6.4	8.9	(28.1%)
Depreciation and amortisation	(3.7)	(3.8)	2.6%
EBIT	2.7	5.1	(47.1%)

FY 2025 was a challenging year for Agilix Biolabs due to geopolitical issues. Prolonged uncertainty and volatility in global health policies, tariffs and funding of biotech and pharmaceutical research resulted in contract delays, and cancellations.

Revenue declined by 3.3% to \$38.2 million in FY 2025. The market downturn impacted EBITDA which declined to \$6.4 million, and EBIT to \$2.7 million.

The period of uncertainty appears to have passed, with the Q1 2026 revenue pipeline recovering and in line with management expectations. As the market has pivoted away from small molecule projects, Agilix is focused on growing large molecule work and strengthening Immunoassay and Immunobiology capabilities.

### CORPORATE

UNDERLYING	2025 \$M	2024 \$M	BETTER/(WORSE) %
Revenue	4.2	4.2	0.0%
EBITDA	(11.3)	(11.2)	(0.9%)
Depreciation and amortisation	(2.5)	(3.7)	32.4%
EBIT	(13.8)	(14.9)	7.4%

Corporate functions include the management of centralised support services where those functions benefit from scale. Corporate costs in FY 2025 were in line with the prior comparative period due to tight cost control and restructuring offsetting inflationary cost pressures. The reduction in depreciation and amortisation relates to a remeasurement of certain right-of-use asset values, resulting in a lower expense.

Healius is well advanced with its cost out program post the Lumus divestment and separation. With a simplified business model post the sale of Lumus Imaging, the target is to remove \$15-\$20 million of support costs by the end of FY 2026.

In FY 2025, \$7.3 million of annualised savings has been achieved as a part of this program. A further \$8.5 million in annualised savings have been identified and will be removed during the course of FY 2026.

## CASH FLOW AND CAPITAL MANAGEMENT

REPORTED	2025 \$M	2024 \$M
Gross cash flows from operating activities	285.7	242.6
Net income tax refund	-	24.2
<b>Net cash flows from operating activities</b>	<b>285.7</b>	<b>266.8</b>
Maintenance capex	(31.3)	(27.6)
<b>Free cash flow</b>	<b>254.4</b>	<b>239.2</b>
Growth capex	(34.6)	(36.4)
Payments relating to acquisitions	-	(2.1)
Proceeds from sale of business, net of transaction costs	795.2	1.0
Proceeds from sale of PPE, and deferred consideration	0.7	2.1
Net interest paid and finance costs (including on lease liabilities)	(73.1)	(69.8)
Payment of lease liabilities	(219.5)	(226.0)
Dividends paid	(299.9)	-
Proceeds from issuing shares, net of transaction costs	-	179.3
Net debt repayment, net of transaction costs	(426.1)	(142.5)
<b>Net decrease in cash</b>	<b>(2.9)</b>	<b>(55.2)</b>

The above includes cash flows from the divested business Lumus Imaging, up to the date of divestment. The prior comparative period includes cashflows for the divested business for the entire financial year.

In FY 2025, Healius' gross operating cash flow conversion was 101% of EBITDA, when adjusting for the cash outflows from non-underlying items, discontinued operations and other non-cash items.

On 1 May 2025, Healius successfully completed the sale of Lumus Imaging, with cash proceeds of \$795.2 million net of transaction costs. The proceeds were used to repay Healius' existing debt facility, and \$299.9 million was used to fund a special dividend of 41.3c per share which was paid to shareholders on 23 May 2025.

Following the repayment of debt, a new three year bank facility of \$300 million maturing in May 2028, has been negotiated to reflect the reduced financing needs of the Group. Standard gearing and interest cover covenants are in place.

As at 30 June 2025, the Group was in a net cash position of \$57.2 million with no drawn debt and was within its banking covenants.

Healium will continue to take a conservative approach to the balance sheet and capital management until earnings consistency is achieved.



## **STRATEGY**

### ***Pathology***

Healius Pathology is a clinically driven diagnostics business with an extensive footprint of 92 Laboratories, 1,982 Collection Centres nationally, and over 200 Pathologists.

Our strategy aims to deliver profitability through lean growth and is focused on providing better services for our patients and referrers to improve the volume and quality of the revenue we generate, and to become more efficient in our processes. This is underpinned by our five strategic pillars summarised below.

#### ***1. Customer service***

Focused on customer-centricity, our goal is to consistently provide high-quality service across all touch points with patients and referrers, through improved technology, training and recruitment in our collection and contact centres. This will strengthen our referrer and customer value propositions through visibly enhancing our service as we improve reporting and turnaround times.

There are three priority areas under this pillar:

- Growing our core business
- Improving network and collections productivity
- Enhancing customer experience

#### ***2. Laboratory modernisation***

We operate a complex network of laboratories across Australia. Simplifying and automating the workflows in our laboratories, standardising processes and enhancing productivity through technology and AI where appropriate is the principal objective.

The three priority areas under this pillar are:

- Improving efficiency and quality of laboratory operations
- Optimisation of logistics, namely our courier fleet and network
- Reduction in consumable spend

The laboratory modernisation work is well underway – the critical objective is to reduce the administrative burden with cost efficiencies as a natural by-product.

#### ***3. Emerging diagnostics***

A priority for the business is to capitalise on new and emerging opportunities.

Diversifying revenue away from MBS and adding higher margin products to our portfolio is key. This strategic pillar includes:

- Genomic Diagnostics
- B2B and B2C offerings, including clinical trials
- Veterinary Pathology

#### ***4. Digital technologies***

Digital technology is a key enabler to achieving our strategy, either through driving revenue growth or enabling efficiencies through automation and process improvement. There are three components of our digital framework:

- Customer facing solutions to improve services for patients and doctors through Healius' Medway suite of customer products
- Clinical systems that underpin core workflow in laboratories through the Pathway suite of clinical products
- A modern data platform that provides a secure infrastructure

Our digital capability is maturing with a suite of digital products that deliver on our key objectives of improving our customer service, modernising our laboratories, and pursuing emerging diagnostic opportunities in growth areas.

### 5. People & ways of working

The national operating model is designed to create a standardised and uniform way of working across the organisation, and to reduce the complexity in our business. This ultimately results in a leaner structure without compromising the quality of our service.

There are three core operational functions being:

- **Customer & Commercial** – focused on improving services for patients and referring doctors across touchpoints including collection and call centres.
- **Laboratory Operations** – efficiently operating the network with standardisation and uniformity. Digital automation, and AI where appropriate will be the significant drivers of step change in efficiency.
- **Clinical Integration** – our Pathologists and Scientists are at the core of everything we do. Led by our Clinical Advisory Council, all clinical decisions are co-ordinated across the organisation with the Council playing an active role in the strategic direction and commercial decision-making process.

Our strategy is founded on patients and referrers. It is enabled by technology, new ways of working within our business and has been communicated and understood by the organisation as a crucial part of our T27 business plan.

### Agilex Biolabs

Agilex' strategy is to grow its global network of Bioanalytical services for drug development by aligning with partners globally.

As a dominant player in Phase 1 Bioanalytical work in Australia, this enables Agilex to diversify its offer to include the benefits of more economical method development to support its customers' Phase 2 and 3 trials globally.

Agilex will continue to innovate in each department to improve labour costs, the utilisation of scientists, and quality assurance functions, to maintain relevance for critical external parties.

## Consolidated statement of profit or loss for the year ended 30 June 2025

	NOTE	2025 \$M	2024 <sup>1</sup> \$M
Revenue	3	1,344.2	1,271.8
Employee benefits expense		(685.7)	(625.0)
Property expenses		(47.0)	(46.1)
Consumables		(214.0)	(203.0)
Repairs and maintenance		(15.9)	(14.5)
IT expenses		(35.8)	(37.5)
Insurance		(7.4)	(7.6)
Other expenses		(113.9)	(102.8)
Depreciation – property, plant and equipment		(27.6)	(27.8)
Depreciation – right of use assets		(187.9)	(189.4)
Amortisation – intangibles		(8.8)	(10.8)
Digital transformation costs	2	(19.6)	(25.8)
Transaction and takeover bid costs	2	(1.6)	(7.5)
Impairment of goodwill	8	(495.2)	(603.2)
Restructuring and other costs	2	(10.8)	(9.2)
<b>Loss before interest and tax</b>		<b>(527.0)</b>	<b>(638.4)</b>
Net finance costs	4	(65.1)	(60.4)
<b>Loss before tax</b>		<b>(592.1)</b>	<b>(698.8)</b>
Income tax benefit	5	29.1	28.8
<b>Loss for the year from continuing operations</b>		<b>(563.0)</b>	<b>(670.0)</b>
Profit from discontinued operations	19	411.8	24.2
<b>Loss for the year</b>		<b>(151.2)</b>	<b>(645.8)</b>
Attributable to:			
<b>Equity holders of Healius Limited</b>		<b>(151.2)</b>	<b>(645.8)</b>

<sup>1</sup>The Lumus Imaging business has been presented as a discontinued operation for the year ended 30 June 2025, with comparatives restated accordingly. Refer to Note 19.

Notes to the financial statements are included on pages 17 to 26.

## Consolidated statement of other comprehensive income for the year ended 30 June 2025

	2025 \$M	2024 \$M
<b>Loss for the year</b>	<b>(151.2)</b>	<b>(645.8)</b>
<b>Other comprehensive loss</b>		
<i>Items that may be reclassified subsequently to profit or loss</i>		
Fair value loss on cash flow hedges	(1.1)	(0.1)
Reclassification adjustments relating to realised cash flow hedges recognised in profit or loss	(1.4)	(1.9)
Exchange differences arising on translation of foreign operations	0.1	(0.2)
Income tax relating to items that may be reclassified subsequently to profit or loss	0.7	0.6
<b>Other comprehensive loss for the year, net of income tax</b>	<b>(1.7)</b>	<b>(1.6)</b>
<b>Total comprehensive loss for the year</b>	<b>(152.9)</b>	<b>(647.4)</b>

Notes to the financial statements are included on pages 17 to 26.

## Consolidated statement of financial position as at 30 June 2025

	NOTE	30 JUNE 2025 \$M	30 JUNE 2024 \$M
<b>Current assets</b>			
Cash	18 (a)	57.2	60.1
Receivables	7	164.9	207.9
Consumables		29.8	31.9
Tax assets		-	0.2
<b>Total current assets</b>		<b>251.9</b>	<b>300.1</b>
<b>Non-current assets</b>			
Goodwill	8	430.0	1,296.7
Right of use assets	12	825.3	1,038.5
Property, plant and equipment	9	113.2	183.4
Other intangible assets	10	56.6	71.8
Receivables	7	3.2	3.2
Deferred tax assets		96.8	89.1
<b>Total non-current assets</b>		<b>1,525.1</b>	<b>2,682.7</b>
<b>Total assets</b>		<b>1,777.0</b>	<b>2,982.8</b>
<b>Current liabilities</b>			
Payables	13	133.9	200.9
Deferred consideration		-	0.5
Tax liabilities		16.0	-
Provisions	14 (a)	115.0	127.6
Lease liabilities	11	181.3	271.3
<b>Total current liabilities</b>		<b>446.2</b>	<b>600.3</b>
<b>Non-current liabilities</b>			
Provisions	14 (b)	12.4	15.2
Interest bearing liabilities	15	-	420.8
Lease liabilities	11	730.5	905.8
<b>Total non-current liabilities</b>		<b>742.9</b>	<b>1,341.8</b>
<b>Total liabilities</b>		<b>1,189.1</b>	<b>1,942.1</b>
<b>Net assets</b>		<b>587.9</b>	<b>1,040.7</b>
<b>Equity</b>			
Issued capital	16	2,604.0	2,603.9
Reserves		0.3	4.1
Accumulated losses		(2,016.4)	(1,567.3)
<b>Total equity</b>		<b>587.9</b>	<b>1,040.7</b>

The consolidated statement of financial position does not include the financial position of the divested Lumus Imaging business as at 30 June 2025. Comparatives have not been restated and continue to include these balances.

Notes to the financial statements are included on pages 17 to 26.

## Consolidated statement of changes in equity for the year ended 30 June 2025

\$M	ISSUED CAPITAL	CASH FLOW HEDGE RESERVE	SHARE-BASED PAYMENTS RESERVE	OTHER RESERVES	ACCUMULATED LOSSES	TOTAL
<b>Balance at 1 July 2024</b>	<b>2,603.9</b>	<b>1.8</b>	<b>3.2</b>	<b>(0.9)</b>	<b>(1,567.3)</b>	<b>1,040.7</b>
Loss for the year	–	–	–	–	(151.2)	(151.2)
Fair value loss on cash flow hedges	–	(1.1)	–	–	–	(1.1)
Reclassification adjustments relating to realised cash flow hedges recognised in profit or loss	–	(1.4)	–	–	–	(1.4)
Differences arising on translation of foreign operations	–	–	–	0.1	–	0.1
Income tax relating to components of other comprehensive income	–	0.7	–	–	–	0.7
<b>Total comprehensive loss</b>	<b>–</b>	<b>(1.8)</b>	<b>–</b>	<b>0.1</b>	<b>(151.2)</b>	<b>(152.9)</b>
Shares issued via Non-Executive Director (NED) Share Plan	0.1	–	–	–	–	0.1
Share based payments	–	–	(0.1)	–	–	(0.1)
Payment of dividends	–	–	–	–	(299.9)	(299.9)
Transfers	–	–	(2.0)	–	2.0	–
<b>Balance at 30 June 2025</b>	<b>2,604.0</b>	<b>–</b>	<b>1.1</b>	<b>(0.8)</b>	<b>(2,016.4)</b>	<b>587.9</b>

Notes to the financial statements are included on pages 17 to 26.

## Consolidated statement of changes in equity for the year ended 30 June 2024

\$M	ISSUED CAPITAL	CASH FLOW HEDGE RESERVE	SHARE-BASED PAYMENTS RESERVE	OTHER RESERVES	ACCUMULATED LOSSES	TOTAL
Balance at 1 July 2023	2,421.0	3.2	6.0	(0.7)	(923.3)	1,506.2
Loss for the year	–	–	–	–	(645.8)	(645.8)
Fair value gain on cash flow hedges	–	(0.1)	–	–	–	(0.1)
Reclassification adjustments relating to realised cash flow hedges recognised in profit or loss	–	(1.9)	–	–	–	(1.9)
Differences arising on translation of foreign operations	–	–	–	(0.2)	–	(0.2)
Income tax relating to components of other comprehensive income	–	0.6	–	–	–	0.6
<b>Total comprehensive loss</b>	–	<b>(1.4)</b>	–	<b>(0.2)</b>	<b>(645.8)</b>	<b>(647.4)</b>
Entitlement offer	187.4	–	–	–	–	187.4
Entitlement offer – fees and transaction costs	(8.2)	–	–	–	–	(8.2)
Entitlement offer – equity tax	2.5	–	–	–	–	2.5
Shares issued via Non-Executive Director (NED) Share Plan	0.1	–	–	–	–	0.1
Share based payments	–	–	0.1	–	–	0.1
Transfers	1.1	–	(2.9)	–	1.8	–
<b>Balance at 30 June 2024</b>	<b>2,603.9</b>	<b>1.8</b>	<b>3.2</b>	<b>(0.9)</b>	<b>(1,567.3)</b>	<b>1,040.7</b>

Notes to the financial statements are included on pages 17 to 26.

## Consolidated statement of cash flows for the year ended 30 June 2025

	NOTE	2025 \$M	2024 \$M
<b>Cash flows from operating activities</b>			
Receipts from customers		1,842.9	1,750.2
Payments to suppliers and employees		(1,557.2)	(1,507.6)
Gross cash flows from operating activities		285.7	242.6
Net income tax refund		-	24.2
<b>Net cash from operating activities</b>	18 (b)	285.7	266.8
<b>Cash flows from investing activities</b>			
Proceeds from sale of business (net of cash disposed and transaction costs)		795.2	1.0
Payment for property, plant and equipment		(54.0)	(50.9)
Payment for other intangibles		(11.9)	(13.1)
Proceeds from the sale of property, plant and equipment and intangibles		1.5	2.1
Payment for business acquired and deferred consideration (net of cash received)		(0.8)	(2.1)
<b>Net cash from/(used in) investing activities</b>		730.0	(63.0)
<b>Cash flows from financing activities</b>			
Finance costs on interest bearing liabilities		(25.7)	(30.6)
Interest received		2.7	1.6
Interest paid on lease liabilities		(50.1)	(40.8)
Payment of lease liabilities		(219.5)	(226.0)
Proceeds from borrowings, net of transaction costs		88.9	47.5
Repayment of borrowings		(515.0)	(190.0)
Proceeds from issuing shares, net of transaction costs		-	179.3
Dividends paid		(299.9)	-
<b>Net cash used in financing activities</b>		(1,018.6)	(259.0)
<b>Net decrease in cash held</b>		(2.9)	(55.2)
Cash at the beginning of the year	18 (a)	60.1	115.3
<b>Cash at the end of the year</b>	18 (a)	57.2	60.1

The consolidated statement of cash flows for the year ended 30 June 2025 includes cash flows from the divested business Lumus Imaging, up to the date of divestment. The prior comparative period includes cashflows for the divested business for the entire financial year.

Notes to the financial statements are included on pages 17 to 26.



### 1. MATERIAL ACCOUNTING POLICIES

Healius Limited (Healius), is a for-profit entity domiciled in Australia. These financial statements represent the consolidated financial statements of Healius for the financial year ended 30 June 2025 and comprise Healius and its subsidiaries (together referred to as “the consolidated entity” or “the Group”).

#### Statement of compliance

The preliminary financial report has been prepared in accordance with ASX Listing Rule 4.3A and the disclosure requirements of ASX Appendix 4E. This preliminary financial report does not include all the notes included with the annual financial report.

#### Basis of preparation

This financial report has been prepared on the basis of historical cost, except for the revaluation of certain financial instruments. Cost is based on the fair values of the consideration given in exchange for assets. All amounts are presented in Australian dollars. The financial report has been prepared on a going concern basis. Notwithstanding that the Group is in a net current liability position as at 30 June 2025 of \$194.3 million (2024: \$300.2 million), management continually monitors the Group’s working capital position, including forecast working capital requirements and available borrowing facilities. The Group’s financial forecasts demonstrate that there are sufficient financial resources to meet obligations as they fall due during the next 12 months.

The accounting policies and methods of computation adopted in the preparation of the preliminary financial report are consistent with those adopted and disclosed in the Group’s annual report for the financial year ended 30 June 2024. These accounting policies are consistent with Australian Accounting Standards and International Financial Reporting Standards.

#### New and amended standards adopted

There are no new accounting standards or interpretations that are applicable for the first time in financial year 2025 which have a material impact on the disclosures or amounts recognised in the consolidated financial statements of the Group. The Group has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective.

#### Rounding of amounts

Healius is an entity of the kind referred to in ASIC Corporations (Rounding in Financial/Directors’ Report) instruments 2016/191, dated 24 March 2016, and in accordance with that Corporations Instrument, amounts in the financial report are rounded to the nearest hundred thousand dollars, unless otherwise indicated.

#### Comparative information

Where necessary, comparative amounts have been reclassified and repositioned for consistency with current period disclosures. Further details on the nature and reason for amounts that have been reclassified and repositioned, where considered material, are referred to separately in the preliminary financial report or notes thereto.

The consolidated statement of profit or loss for the year ended 30 June 2025 does not include results of the divested Lumus Imaging business in continuing operations, and the comparative information has been restated to also exclude the results of Lumus Imaging, which are now included as part of discontinued operations (Note 19). The consolidated statement of financial position does not include Lumus Imaging as at 30 June 2025, but the financial position of Lumus Imaging is included in the prior comparative period. The consolidated statement of cash flows includes Lumus Imaging in the current period up to the date of divestment (1 May 2025). The prior comparative period includes cashflows for the divested business for the full financial year.

## 2. SEGMENT INFORMATION

Operating segments are identified based on the way that the Chief Executive Officer and Board of Directors (also collectively known as the chief operating decision makers) regularly review and assess the financial performance of the business and determine the allocation of resources. After the disposal of the Lumus Imaging business, the Group has only one reportable segment based on similar economic characteristics, being a provider of pathology services. As a result, the reportable segment information is as disclosed in the financial statements.

The Group operates predominantly in Australia.

For internal management reporting purposes, the chief operating decision makers review and assess the financial performance based on underlying results. Underlying results exclude the impact of impairment expenses and non-underlying items relating to:

- Strategic initiatives; and
- Other significant non-recurring items.

### Reconciliation of underlying segment result to reported loss before interest and tax

	2025 \$M	2024 \$M
<b>Underlying results from continuing operations before interest and tax</b>	<b>17.1</b>	23.5
Digital transformation costs	(19.6)	(25.8)
Transaction and takeover bid costs	(1.6)	(7.5)
Impairment of goodwill	(495.2)	(603.2)
Restructuring and other costs	(10.8)	(9.2)
Transactions with discontinued operations	(16.9)	(16.2)
<b>Reported loss before interest and tax</b>	<b>(527.0)</b>	(638.4)

## 3. REVENUE

	2025 \$M	2024 \$M
Trading revenue	<b>1,344.2</b>	1,271.8

## 4. NET FINANCE COSTS

	2025 \$M	2024 \$M
Interest expense	<b>24.9</b>	28.8
Interest on lease liabilities	<b>38.8</b>	30.4
Amortisation of borrowing costs	<b>1.4</b>	1.2
	<b>65.1</b>	60.4

**5. INCOME TAX BENEFIT**

	2025 \$M	2024 \$M
The prima facie income tax benefit on the pre-tax accounting loss reconciles to the income tax benefit in the financial statements as follows:		
Loss before tax	(592.1)	(698.8)
Income tax calculated at 30% (2024: 30%)	(177.6)	(209.6)
Tax effect of non-temporary differences:		
Non-deductible asset impairment expense	148.6	180.9
Other non-deductible items	0.1	-
Over provision in prior years	(0.2)	(0.1)
Income tax benefit	(29.1)	(28.8)

**6. EARNINGS PER SHARE**
**Basic and diluted earnings per share**

EARNINGS	2025 \$M	2024 \$M
The earnings used in the calculation of basic and diluted earnings per share are the same and can be reconciled to the consolidated statement of profit or loss as follows:		
Loss for the year from continuing operations	(563.0)	(670.0)
Loss attributable to equity holders of Healius Limited	(151.2)	(645.8)

EARNINGS PER SHARE	2025 CENTS	2024 CENTS
Basic loss per share	(20.8)	(97.9)
Basic underlying loss per share	(3.4)	(2.4)
Diluted loss per share	(20.8)	(97.9)
Diluted underlying loss per share	(3.4)	(2.4)

Any share options and performance rights on issue are contingently issuable shares. They are included in the calculation of diluted earnings per share only when the performance conditions have been met.

**7. RECEIVABLES**

	2025 \$M	2024 \$M
Measured at amortised cost		
Current		
Trade receivables	128.3	170.5
Allowance for expected credit losses	(23.6)	(28.3)
	104.7	142.2
Prepayments	15.8	20.4
Accrued revenue	40.2	38.5
Other receivables	4.2	6.8
	164.9	207.9
Non-current		
Other receivables	2.1	3.2
Prepayments	1.1	-
	3.2	3.2

## 8. GOODWILL

	2025 \$M	2024 \$M
<b>Carrying value</b>		
Opening balance	1,296.7	1,897.5
Acquisition of businesses	-	2.4
Impairment of goodwill	(495.2)	(603.2)
Business divestments <sup>1</sup>	(371.5)	-
<b>Closing balance</b>	<b>430.0</b>	<b>1,296.7</b>
Goodwill is allocated to the Group's cash-generating units (CGUs) as follows:		
Pathology	430.0	925.2
Imaging <sup>1</sup>	-	371.5
	<b>430.0</b>	<b>1,296.7</b>

<sup>1</sup> Goodwill allocated to the Imaging CGU is included in the divestment of the Imaging business (refer to Note 19).

The carrying amount of goodwill is tested for impairment annually at 30 June and whenever there is an indicator that the asset may be impaired. Where an asset is deemed to be impaired, it is written down to its recoverable amount.

In its impairment assessment, the Group determines the recoverable amount based on a fair value less costs of disposal calculation, under a five-year discounted cash flow model cross checked to available market data. The five-year discounted cash flow uses:

- Year one cash flows derived from the financial year 2026 risk-adjusted Board approved budget; and
- For financial years 2027 – 2030, growth rates have been determined with reference to historical company experience, industry data and a long-term growth rate expected for the industry.

As required by Accounting Standards, a non-cash impairment charge of \$495.2 million has been made to goodwill in the current financial year.

## 9. PROPERTY, PLANT AND EQUIPMENT

2025 \$M	PLANT AND EQUIPMENT	LEASEHOLD IMPROVEMENTS	ASSETS UNDER CONSTRUCTION	TOTAL
<b>Net book value</b>				
Opening balance	99.1	77.5	6.8	183.4
Additions	9.2	1.5	16.4	27.1
Capitalisation of assets under construction	5.7	4.8	(10.5)	-
Disposals	(1.2)	(0.3)	-	(1.5)
Depreciation expense	(19.5)	(11.0)	-	(30.5)
Business divestment	(28.9)	(29.7)	(6.7)	(65.3)
<b>Closing balance</b>	<b>64.4</b>	<b>42.8</b>	<b>6.0</b>	<b>113.2</b>
<b>Cost</b>	<b>239.8</b>	<b>119.7</b>	<b>6.0</b>	<b>365.5</b>
Accumulated depreciation and impairment	(175.4)	(76.9)	-	(252.3)
<b>Closing balance</b>	<b>64.4</b>	<b>42.8</b>	<b>6.0</b>	<b>113.2</b>

9. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

2024 \$M	PLANT AND EQUIPMENT	LEASEHOLD IMPROVEMENTS	ASSETS UNDER CONSTRUCTION	TOTAL
Net book value				
Opening balance	103.8	63.9	8.3	176.0
Additions	23.5	4.0	25.8	53.3
Capitalisation of assets under construction	4.5	22.8	(27.3)	-
Disposals	(5.5)	(0.3)	-	(5.8)
Depreciation expense	(27.2)	(12.9)	-	(40.1)
Closing balance	99.1	77.5	6.8	183.4
Cost	351.7	184.3	6.8	542.8
Accumulated depreciation and impairment	(252.6)	(106.8)	-	(359.4)
Closing balance	99.1	77.5	6.8	183.4

10. OTHER INTANGIBLE ASSETS

2025 \$M	IT SOFTWARE	LICENCES	INTANGIBLES UNDER CONSTRUCTION	TOTAL
Net book value				
Opening balance	51.9	9.5	10.4	71.8
Additions	0.1	-	11.6	11.7
Capitalisation of intangible assets under construction	15.7	(2.9)	(12.8)	-
Disposals	(1.7)	-	-	(1.7)
Amortisation expense	(9.0)	(0.5)	-	(9.5)
Business divestment	(11.0)	(4.6)	(0.1)	(15.7)
Closing balance	46.0	1.5	9.1	56.6
Cost	155.1	5.6	9.1	169.8
Accumulated amortisation and impairment	(109.1)	(4.1)	-	(113.2)
Closing balance	46.0	1.5	9.1	56.6

2024 \$M	IT SOFTWARE	LICENCES	INTANGIBLES UNDER CONSTRUCTION	TOTAL
Net book value				
Opening balance	51.7	7.3	14.1	73.1
Additions	0.3	-	12.8	13.1
Capitalisation of intangible assets under construction	13.5	3.0	(16.5)	-
Disposals	-	-	-	-
Amortisation expense	(13.6)	(0.8)	-	(14.4)
Closing balance	51.9	9.5	10.4	71.8
Cost	167.1	43.3	10.4	220.8
Accumulated amortisation and impairment	(115.2)	(33.8)	-	(149.0)
Closing balance	51.9	9.5	10.4	71.8

## 11. LEASE LIABILITIES

	2025 \$M	2024 \$M
Opening balance	1,177.1	1,203.9
New leases and remeasurements	193.0	199.2
Business divestment	(267.0)	-
Interest	41.4	40.8
Payments	(232.7)	(266.8)
Closing balance	911.8	1,177.1
Presented as:		
Current lease liabilities	181.3	271.3
Non-current lease liabilities	730.5	905.8
Total lease liabilities	911.8	1,177.1

## 12. RIGHT OF USE ASSETS

	2025 \$M	2024 \$M
Opening balance	1,038.5	1,067.3
New leases and remeasurements	194.2	203.7
Depreciation	(197.4)	(226.7)
Business divestment	(210.0)	-
Impairment	-	(5.8)
Closing Balance	825.3	1,038.5

## 13. PAYABLES

	2025 \$M	2024 \$M
Current		
Trade payables and accruals	133.9	200.9
Total payables	133.9	200.9

## 14. PROVISIONS

	2025 \$M	2024 \$M
(a) Current		
Provision for employee benefits	86.6	113.5
Self-insurance provision	7.1	7.1
Other current provisions	21.3	7.0
	115.0	127.6
(b) Non-current		
Provision for employee benefits	6.7	8.4
Self-insurance provision	5.1	4.0
Other non-current provisions	0.6	2.8
	12.4	15.2

## 15. INTEREST BEARING LIABILITIES

	2025 \$M	2024 \$M
<b>Non-current</b>		
Gross bank loans	-	425.0
Unamortised borrowing costs	-	(4.2)
<b>Closing Balance</b>	-	420.8

The Group had access to the following financing facilities as at the end of the reporting period:

	2025 \$M	2024 \$M
<b>Financing facilities</b>		
<b>Non-current</b>		
<i>Unsecured Syndicated Debt Facilities</i>		
Amount used	-	425.0
Amount unused	300.0	255.0
<b>Closing balance</b>	300.0	680.0

The Group refinanced its debt arrangements following the receipt of proceeds from the sale of Lumus Imaging. The new facility matures in May 2028 and, consistent with the previous facility, includes earnings to debt and earnings to interest-based covenants.

Amounts unused on non-current facilities can be drawn during the ordinary working capital cycle of the Group.

## 16. ISSUED CAPITAL

	2025 NO. OF SHARES 000'S	2024 NO. OF SHARES 000'S	2025 \$M	2024 \$M
<b>Opening balance</b>	<b>726,101</b>	569,529	<b>2,603.9</b>	2,421.0
Shares issued via Short Term Incentive Plan (deferred equity)	-	210	-	0.8
Shares issued via Non-Executive Director Share Plan	32	59	0.1	0.1
Shares issued via Long Term Incentive Plan	-	155	-	0.3
Shares issued via Entitlement Offer, net of transaction costs	-	156,148	-	181.7
<b>Closing balance</b>	<b>726,133</b>	726,101	<b>2,604.0</b>	2,603.9

Issued capital consists of fully paid ordinary shares carrying one vote per share and the right to dividends.

Transaction costs that are incurred directly in connection with the issue of equity instruments are recognised directly in equity as a reduction of the proceeds of the equity instruments to which the costs relate.

## 17. DIVIDENDS ON EQUITY INSTRUMENTS

	2025 CENTS PER SHARE	2024 CENTS PER SHARE	2025 \$M	2024 \$M
<b>Recognised amounts</b>				
Final dividend – previous financial year	-	-	-	-
Interim dividend – this financial year	-	-	-	-
Special dividend – this financial year	41.3	-	299.9	-
	<b>41.3</b>	-	<b>299.9</b>	-

There were no unrecognised dividend amounts in this financial year. No dividends are expected to be paid for the year ended 30 June 2025.

17. DIVIDENDS ON EQUITY INSTRUMENTS (CONTINUED)

FRANKING ACCOUNT	2025 \$M	2024 \$M
Closing balance as at 30 June	32.2	160.7

18. NOTES TO THE STATEMENT OF CASH FLOWS

	NOTE	2025 \$M	2024 \$M
<b>(a) Reconciliation of cash</b>			
For the purpose of the statement of cash flows, cash includes cash on hand and in banks.		57.2	60.1
Cash at the end of the financial year as shown in the statement of cash flows is reconciled to the related items in the statement of financial position as follows:			
Cash as disclosed in statement of financial position			
<b>Cash as disclosed in the Group statement of cash flows</b>		<b>57.2</b>	<b>60.1</b>
<b>(b) Reconciliation of loss from ordinary activities after related income tax to net cash flows from operating activities</b>			
Loss for the year		(151.2)	(645.8)
Net finance costs		76.5	70.8
Depreciation of property, plant and equipment		30.5	40.1
Depreciation of right of use asset		197.4	226.7
Amortisation of intangibles		9.5	14.4
Gain on sale of Lumus Imaging	19	(375.2)	-
Gain on derecognition of right of use asset		(2.9)	(5.2)
Loss on sale of property, plant and equipment and intangibles		0.9	0.5
Impairment of leased assets		-	5.8
Impairment of goodwill	8	495.2	603.2
Other non-cash items		-	(0.1)
Increase/(decrease) in:			
Trade payables and accruals		(12.9)	(6.3)
Provisions		3.0	(18.4)
Deferred revenue		0.7	(7.0)
Income tax and deferred taxes		0.2	8.4
Decrease/(increase) in:			
Consumables		(0.9)	0.9
Receivables and prepayments		14.9	(21.2)
<b>Net cash provided by operating activities<sup>1</sup></b>		<b>285.7</b>	<b>266.8</b>

<sup>1</sup> Net cash provided by operating activities for the year ended 30 June 2025 includes cash flows from the divested business, Lumus Imaging, up to the date of divestment. The prior comparative period includes cashflows for the divested business for the entire financial year.

Financing facilities

Details of financing facilities available to the Group are provided in Note 15.



## 19. DISCONTINUED OPERATIONS

The Group sold the Lumus Imaging business on 1 May 2025. The results of the business have been presented as discontinued operations.

The results of discontinued operations for the year are as follows:

	2025 \$M	2024 \$M
Revenue	458.1	474.4
Expenses	(377.4)	(426.6)
<b>Earnings before interest and tax</b>	<b>80.7</b>	47.8
Finance costs	(14.8)	(10.4)
<b>Profit before tax</b>	<b>65.9</b>	37.4
Profit on sale <sup>1</sup>	375.2	-
<b>Profit before tax from discontinued operations</b>	<b>441.1</b>	37.4
Income tax expense	(29.3)	(13.2)
<b>Profit from discontinued operations</b>	<b>411.8</b>	24.2

<sup>1</sup> The profit on sale includes transaction, separation and other costs associated with the divestment of Lumus Imaging. This includes adviser fees, incentive payments and impact of refinancing.

The profit on sale is calculated based on proceeds received on completion less a provision for completion adjustments. These adjustments will be agreed with the purchaser in the ordinary course of business, and may or may not result in further adjustment.

During the period, the Group received a tax position paper from the Australian Tax Office (ATO) in relation to the treatment of lump sum payments made to healthcare practitioners (HCPs) from 2019 to 2022. These payments were made to HCPs in the previously sold Medical Centres and Lumus Imaging businesses. The Group reached a settlement with the ATO and has recognised a liability of \$22.7 million at 30 June 2025 based on the notice of amended assessments received by the Group. This includes amounts payable for income tax, interest and penalties, and has been reflected in the discontinued operations results above.

The net cash flows of discontinued operations are:

	2025 \$M	2024 \$M
Operating	83.5	67.8
Investing	760.0	(25.8)
Financing	(52.7)	(57.7)
<b>Net cash inflow/(outflow)</b>	<b>790.8</b>	(15.7)

The profit per share attributable to discontinued operations is as follows:

	2025 Cents	2024 Cents
Basic profit per share from discontinued operations	56.7	3.7
Diluted profit per share from discontinued operations	56.7	3.7

**20. SUBSEQUENT EVENTS**

There has not been any matter or circumstance that has arisen since the end of the financial year that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

**21. NET TANGIBLE ASSET/(LIABILITY) BACKING**

	2025 \$	2024 \$
Net tangible asset/(liability) backing per share	0.01	(0.63)

Net tangible asset/(liability) backing is calculated based upon net assets excluding goodwill, deferred taxation and other intangible assets.

## Compliance Statement for the year ended 30 June 2025

---

This report has been prepared in accordance with AASB Standards, other AASB authoritative pronouncements and Urgent Issues Group Consensus Views or other standards acceptable to ASX.

Identify other standards used

NIL

This report, and the accounts upon which the report is based (if separate), use the same accounting policies.

This report gives a true and fair view of the matters disclosed.

This report is based on accounts to which one of the following applies.  
(Tick one)

- |   |   |
|---|---|
| <input type="checkbox"/> The accounts have been audited.                              | <input type="checkbox"/> The accounts have been subject to review.                  |
| <input checked="" type="checkbox"/> The accounts are in the process of being audited. | <input type="checkbox"/> The accounts have <i>not</i> yet been audited or reviewed. |

If the audit report or review by the auditor is not attached, details of any qualifications will follow immediately they are available.

The entity has a formally constituted audit committee.

Sign here:

Date: 21 August 2025



(Director)

Print name: Paul Anderson